These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 2876796)

  • 41. Terazosin: a new long-acting alpha 1-adrenergic antagonist for hypertension.
    Frishman WH; Eisen G; Lapsker J
    Med Clin North Am; 1988 Mar; 72(2):441-8. PubMed ID: 2894488
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Reversal of left ventricular hypertrophy by terazosin in hypertensive patients.
    Yasumoto K; Takata M; Yoshida K; Mikawa M; Tomoda F; Sasayama S
    J Hum Hypertens; 1990 Feb; 4(1):13-8. PubMed ID: 1971654
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Clinical pharmacology and therapeutic role of prazosin and related alpha-adrenoceptor antagonists.
    Reid JL; Vincent J
    Cardiology; 1986; 73(3):164-74. PubMed ID: 2872958
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Concomitant administration of terazosin and atenolol for the treatment of essential hypertension.
    Holtzman JL; Kaihlanen PM; Rider JA; Lewin AJ; Spindler JS; Oberlin JA
    Arch Intern Med; 1988 Mar; 148(3):539-43. PubMed ID: 3277569
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [The use of terazosin hydrochloride (Hytrin) in the treatment of patients with benign prostatic hyperplasia].
    Sivkov AV; Apolikhin OI; Medvedev AA
    Urol Nefrol (Mosk); 1997; (5):50-3. PubMed ID: 9412019
    [No Abstract]   [Full Text] [Related]  

  • 46. Long-term efficacy and safety of terazosin alone and in combination with other antihypertensive agents.
    Cohen JD
    Am Heart J; 1991 Sep; 122(3 Pt 2):919-25. PubMed ID: 1678923
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Long-term experience with terazosin for treatment of mild to moderate hypertension.
    Mersey JH
    Am J Med; 1986 May; 80(5B):68-72. PubMed ID: 2872810
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Efficacy of terazosin in the treatment of essential hypertension in blacks.
    Luther RR; Klepper MJ; Maurath CJ; Glassman HN; Achari R; Laddu AR
    J Hum Hypertens; 1990 Apr; 4(2):151-3. PubMed ID: 1971027
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [The effect of terazosin and nitrendipine on blood insulin, glucose and lipid in SHR rats].
    Wang W
    Zhonghua Xin Xue Guan Bing Za Zhi; 1993 Aug; 21(4):234-5. PubMed ID: 7910793
    [No Abstract]   [Full Text] [Related]  

  • 50. A multicentre, hospital study of the efficacy and safety of terazosin and its effects on the plasma cholesterol levels of patients with untreated essential hypertension.
    Lytle T; Coles S; Waite MA
    J Hum Hypertens; 1991 Feb; 5(1):35-8. PubMed ID: 1674964
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The role of alpha 1-blockers in combination therapy for hypertension.
    Zusman RM
    Int J Clin Pract; 2000; 54(1):36-40. PubMed ID: 10750258
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Antihypertensive effectiveness of terazosin: a new long-acting alpha-adrenergic inhibitor.
    Chrysant SG; Bal IS; Johnson B; McPherson MA
    Clin Cardiol; 1985 Sep; 8(9):486-9. PubMed ID: 2864153
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The relationship between terazosin dose and blood pressure response in hypertensive patients.
    Achari R; Hosmane B; Bonacci E; O'Dea R
    J Clin Pharmacol; 2000 Oct; 40(10):1166-72. PubMed ID: 11028256
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Efficacy of terazosin as an antihypertensive agent.
    Luther RR; Glassman HN; Jordan DC; Sperzel WD
    Am J Med; 1986 May; 80(5B):73-6. PubMed ID: 2872811
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Effects of long-term prazosin therapy on lipoprotein metabolism in hypertensive patients.
    Takabatake T; Ohta H; Maekawa M; Yamamoto Y; Ishida Y; Hara H; Hattori N
    Am J Med; 1984 Feb; 76(2A):113-6. PubMed ID: 6367446
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A comparison of the effects of the selective peripheral alpha 1-blocker terazosin with the selective beta 1-blocker atenolol on blood pressure, exercise performance and the lipid profile in mild-to-moderate essential hypertension.
    Ligueros M; Unwin R; Wilkins MR; Humphreys J; Coles SJ; Cleland J
    Clin Auton Res; 1992 Dec; 2(6):373-81. PubMed ID: 1290920
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Relationships between pharmacokinetics and blockade of agonist-induced prostatic intraurethral pressure and mean arterial pressure in the conscious dog after single and repeated daily oral administration of terazosin.
    Witte DG; Brune ME; Katwala SP; Milicic I; Kerwin JF; Hancock AA
    J Pharmacol Exp Ther; 1997 Aug; 282(2):891-8. PubMed ID: 9262356
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Effect of terazosin on blood pressure and serum lipids.
    Gong P; Tang J; Cheng L; Lu Z; Zhang J; Zeng F
    J Tongji Med Univ; 1999; 19(4):291-4. PubMed ID: 12938521
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Effect of age on pharmacokinetics of and blood pressure responses to prazosin and terazosin.
    McNeil JJ; Drummer OH; Conway EL; Workman BS; Louis WJ
    J Cardiovasc Pharmacol; 1987 Aug; 10(2):168-75. PubMed ID: 2441167
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Terazosin in mild hypertension: experience in open trials.
    Rosenthal J
    Br J Clin Pract Suppl; 1987 Dec; 54():32-44. PubMed ID: 2905160
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.